WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
What we know about the Iranian president's helicopter crashTens of thousands protest against Mexico's president in the main square of Mexico City6 people killed, 10 others injured in Idaho when pickup crashes into passenger vanDive team finds bodies of 2 men dead inside plane in Alaska lakeDive team finds bodies of 2 men dead inside plane in Alaska lakeWood scores 2 as Nottingham Forest ensures Premier League survival by beating BurnleyStolen antique weathervane recovered 40 years later and returned to VermontGantz threatens to quit Israel's government over Gaza war strategyKristen Faulkner bounces back from time trial disappointment to win US cycling road race titleKeller pitches 6 effective innings as the Pirates edge the Cubs 3
2.5661s , 6498.09375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Stellar Storyline news portal